Cooperation between Zedira and Cardiff University
Transglutaminase 6 is the focus of new research into ataxia
Advertisement
Zedira and Cardiff University have initiated a joint project addressing questions regarding the role of an enzyme called transglutaminase 6 in the pathophysiology of neurodegenerative diseases. This work builds on and extends previous successful collaborations between the two partners in the arena of the autoantibody response in gluten-related disorders.
Cerebellar ataxias are a heterogeneous group of neurodegenerative diseases affecting primarily the hind brain and are characterized by progressive imbalance and limb movement deficits. Both, genetic and immune-mediated deficiencies in transglutaminase 6 have been implicated in specific forms of adult onset cerebellar ataxia. Within this new project the partners aim to elucidate the underlying processes that ultimately cause disease. A molecular understanding of the disease process and identification of mechanistic links to other ataxias will inform the design of strategies for therapeutic intervention.
Ralf Pasternack / Martin Hils, CEO Zedira: “We are excited about working with Prof. Aeschlimann’s research group with world-leading expertise in this area”.
Daniel Aeschlimann, Cardiff University comments: “The combination of Zedira’s molecular tools, drug candidates and know-how in the transglutaminase field with our scientific expertise is a solid fundament for addressing this thus far unexplored research area”.
Other news from the department science
